)
)
Edge16 Oct 2026
Winner, Winner: The Chicken McNugget Story
How a 1940s breeding contest, a Cornell food scientist, and a hedge by Ray Dalio helped McDonald's turn the Chicken McNugget into a fast-food icon.
Spago Nanomedical
Spago Nanomedical (SPAGO) investor relations material
Spago Nanomedical Q3 2026 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q3 2026 earnings summary5 Nov, 2026
Executive summary
Q3 net sales were KSEK 0 (KSEK 14 YoY), total income KSEK 302 (KSEK 1,250), and net loss KSEK 4,377 (KSEK 6,265).
Tumorad-01 phase I is nearing completion: 15 patients dosed, maximum tolerated dose of 20 MBq/kg identified, and two more patients planned at 15 MBq/kg to define the phase II dose.
The board proposed delisting to improve prospects for raising capital for Tumorad phase II; shareholder approval is scheduled for 19 November 2026.
Financial highlights
Jan–Sep revenue was KSEK 3,762 (KSEK 3,988 YoY), mainly Australian innovation support; net sales were KSEK 0 (KSEK 433).
Jan–Sep operating expenses were KSEK 24,751 (KSEK 24,823); operating result was KSEK -20,989 (KSEK -20,834) and net loss KSEK 20,713 (KSEK 20,664).
Q3 operating expenses were KSEK 4,766 (KSEK 7,568); operating result was KSEK -4,464 (KSEK -6,318).
Outlook and guidance
Near-term priorities: complete Tumorad-01 phase I, define the recommended phase II dose, prepare US Orphan Drug Designation filing for adenoid cystic carcinoma, and advance phase IIa preparations.
Phase IIa is expected to require substantially more capital; delisting is intended to improve access to long-term specialist investors, but does not guarantee financing.
Continued SpagoPix clinical development is contingent on a partner, out-licensing, commercial collaboration, or other external financing.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from Spago Nanomedical
- Delisting proposed to fund Tumorad’s next phase as Phase I reaches completion.SPAGO
Status update - Promising clinical data support a novel radiopharmaceutical platform targeting underserved tumors.SPAGODNB Carnegie Micro Cap Day Conference
- Tumorad-01 met a key endpoint; cash strengthened by rights issue despite ongoing losses.SPAGOQ2 2026
- Tumorad clinical focus and narrowed losses define 2024, with strong equity and cash position.SPAGOQ4 2024
- Tumorad-01 achieved a major clinical milestone as financials improved and phase II preparations advance.SPAGOQ1 2026
- Proof-of-concept for Tumorad achieved; financials improved and liquidity strengthened.SPAGOQ4 2025
- Promising clinical results and safety profile drive expansion of a novel radiopharma platform.SPAGOLife Science Summit 2025
- Tumorad achieved clinical proof-of-concept; losses narrowed and cash reserves declined.SPAGOQ3 2025
- Tumorad clinical progress and cost reductions drive value, with focus on safety and future partnerships.SPAGOQ2 2025
Next Spago Nanomedical earnings date
Q4 20265 Feb, 2027
Spago Nanomedical
Next Spago Nanomedical earnings date
Q4 20265 Feb, 2027
AI chat
Ask anything. Verify everything.
Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn moreFind what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.)
Trust every finding
50m+ first-party documents. Every output traceable to its source.Find what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.Trust every finding
50m+ first-party documents. Every output traceable to its source.Automations
Zero in on what matters
Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more)
Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.)
Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Live audio & transcripts
Be first
Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more)
Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.)
Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Quartr MCP connects your AI environment to 17K+ public companies
Pull live transcripts, filings, and slides into Claude or Codex via MCP. Combine Quartr's global IR data with any other dataset. Run agentic research and monitoring.
Included with Quartr Pro at no extra cost.Learn more
Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.
Jamie Ross
Investment Manager, GAM Investments
GAM
GAM
Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.
Tom O'Hara
Investment Director
Ciena
Ciena
Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.
Gregg Lampf
VP of Investor Relations
Protean
Protean
Being able to ask specific questions across years of transcripts and reports and instantly get verified answers is a game-changer.
Pontus Dackmo
CEO & Investment Manager
)
)
Frequently asked questions
Spago Nanomedical AB is a Swedish biotechnology company that specializes in nanomedicine for cancer diagnostics and treatment. The company is advancing two main projects: SpagoPix and Tumorad. SpagoPix is an MRI contrast agent under clinical development, aimed at improving cancer diagnostics by selectively enhancing tumor visibility in breast, liver, and pancreatic cancers. Tumorad is a radionuclide therapy that targets cancer cells using nanoparticles, currently in preclinical stages for treating advanced cancers. Spago Nanomedical is based in Lund, Sweden, and its shares are listed on the Stockholm Stock Exchange.